Form 8-K OCULAR THERAPEUTIX, INC For: Aug 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Clear Street Reiterates Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:11 AM EDTClear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "OCUL is trading down (-6%, XBI +/- 0%) after reporting 2Q25 earnings. Revenue was roughly in line ($13.5M vs $13.6M) and expenses outpaced expectations ($51.1M vs $43.1M). But we believe the weakness today is caused by the disclosure that the company tapped into its ATM for $97M in... More
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:07 AM EDTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "Tuesday, before market open, Ocular Therapeutix reported 2Q25 financial results. Management hosted a call to discuss recent progress and outlook for the remainder of 2025. The company reported $13.5M in total revenue vs. our estimated $12.0M and diluted EPS of $(0.39) vs. our... More
